GS-5885

Known as: GS 5885, GS5885, WHO 9796 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
012320122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Ledipasvir (LDV; GS-5885), a component of Harvoni (a fixed-dose combination of LDV with sofosbuvir [SOF]), is approved to treat… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
Review
2015
Review
2015
OBJECTIVES To review the pharmacology, efficacy, and safety of ledipasvir-sofosbuvir for the treatment of chronic hepatitis C… (More)
  • table 1
  • table 2
Is this relevant?
2014
2014
A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1… (More)
Is this relevant?
2014
2014
GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Review
2014
Review
2014
Recent progress in the understanding of hepatitis C virus (HCV) biology and the availability of in vitro models to study its… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
GS-5885 is a novel hepatitis C virus (HCV) NS5A inhibitor. In a 3-day monotherapy study in treatment-naive genotype 1a (GT1a) and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
BACKGROUND Hepatitis C virus (HCV) NS5A replication complex inhibitors (RCIs) have been shown to exhibit picomolar antiviral… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND & AIMS GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of genotype… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?